What Is Livagen? Dosage, Half-Life & How to Track It

What Livagen is and how it works

Livagen is a synthetic tetrapeptide built from four amino acids — lysine, glutamic acid, aspartic acid, alanine (Lys-Glu-Asp-Ala) — another member of the Khavinson bioregulator family, developed for research into cellular aging.

Two mechanisms show up in the preclinical literature. First, Livagen strongly inhibits enkephalin-degrading peptidases — enzymes that break down the body's own opioid-like signaling peptides. Second, and more central to why it is grouped with the "anti-aging" bioregulators, it appears to induce heterochromatin decondensation in aged cells — loosening tightly packed, transcriptionally silent DNA so previously dormant genes can be expressed again. That is the epigenetic mechanism proposed across most of this peptide class.

As with the rest of this family, there is no standardized human dosing and no controlled clinical trial behind it — what exists is cell-culture and preclinical animal work. Any protocol you see, including the one below, is a community convention derived by analogy, not a clinically validated regimen.

Typical dosing & reconstitution

Livagen is reconstituted with bacteriostatic water — a 20 mg vial mixed with 3.0 mL gives roughly 6.67 mg/mL, where one U-100 insulin-syringe unit is about 0.0667 mg (66.7 mcg).

Because there's no established human dose, the community pattern is a slow step-up over two to three months rather than a fixed daily amount from day one:

The early 7.5-unit dose is small enough that a standard 100-unit syringe makes it hard to read accurately — a 30- or 50-unit insulin syringe gives finer graduations for the first couple of weeks.

Half-life & what it means for frequency

No human pharmacokinetic study has measured Livagen's half-life. The once-daily schedule isn't derived from a clearance curve — it mirrors how the compound is used in the available preclinical work and how other short bioregulator peptides in this family are typically dosed.

Practically, that means there's no data-backed reason to split the dose, and no data-backed reason not to — the titration schedule above is a slow ramp built for tolerability, not pharmacokinetics.

What to track & possible side effects

Human safety data on Livagen is limited to what these preclinical studies report incidentally; there is no dedicated human tolerability trial. Standard peptide-handling cautions apply — sourcing, sterile technique, and rotating injection sites to avoid local irritation.

Given the slow, multi-month titration, the practical tracking need is remembering which week and dose phase you're in and logging the dose consistently — easy to lose track of by week six without a calendar doing it for you.

Frequently asked questions